8-K: Immunocore Unveils 2026 Strategic Priorities, Strong Cash

Immunocore Holdings plc announced its 2026 strategic priorities, highlighted by clinical trial advancements across oncology, infectious, and autoimmune diseases, alongside a preliminary year-end 2025 cash position of $864 million.

Summary

• Immunocore Holdings plc reported a preliminary, unaudited cash, cash equivalents, and marketable securities balance of approximately $864 million as of December 31, 2025.
• The company outlined key strategic priorities for 2026, focusing on growing KIMMTRAK, expanding beyond melanoma into other tumor types, and realizing growth opportunities in infectious and autoimmune diseases.
• Enrollment completion for the Phase 3 TEBE-AM trial in previously treated cutaneous melanoma is anticipated in the first half of 2026, with topline data expected as early as the second half of 2026.
• Long-term 5-year Overall Survival (OS) data from the Phase 3 tebentafusp trial in metastatic uveal melanoma is expected in the first half of 2026.
• Data from multiple Phase 1/2 trials for PRAME bispecific candidates (brenetafusp and IMC-P115C) in ovarian, non-small cell lung cancer, and other solid tumors are expected in the second half of 2026.
• The first patient in a Phase 1 type 1 diabetes trial (IMC-S118AI) is planned to be dosed in the first half of 2026, and a clinical trial application for a second autoimmune candidate (IMC-U120AI) in atopic dermatitis is expected in the second half of 2026.
• Additional Phase 1 HIV data (IMC-M113V) is slated for presentation in the second half of 2026.
• The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

Sentiment

Score: 8

Explanation: The filing presents a very positive outlook with a strong cash position, significant progress across a broad clinical pipeline, and multiple anticipated data readouts and trial initiations in high-need areas. The company is actively expanding its commercial reach and developing new indications for its approved product, KIMMTRAK, while also advancing novel candidates in infectious and autoimmune diseases. The only minor negative is the expectation of moderating revenue growth for KIMMTRAK, which is typical for a product entering its fifth year post-approval.

Positives

• Strong preliminary cash, cash equivalents, and marketable securities of approximately $864 million at year-end 2025, providing significant financial runway.
• KIMMTRAK continues to be the global standard of care in first-line metastatic uveal melanoma, demonstrating sustained commercial success and market penetration.
• Anticipated completion of enrollment for the Phase 3 TEBE-AM trial in previously treated cutaneous melanoma in 1H 2026, with potential for topline data readout as early as 2H 2026, indicating rapid progress towards expanding KIMMTRAK's indications.
• Expected presentation of long-term 5-year Overall Survival data for tebentafusp in metastatic uveal melanoma in 1H 2026, which could further solidify its efficacy profile.
• Multiple data readouts planned for 2H 2026 across a broad pipeline, including PRAME bispecific candidates in ovarian and lung cancer, and initial data for the half-life extended candidate (IMC-P115C), showcasing pipeline advancement.
• Initiation of a Phase 1 trial for a type 1 diabetes candidate (IMC-S118AI) in 1H 2026 and planned CTA submission for an atopic dermatitis candidate (IMC-U120AI) in 2H 2026, marking significant expansion into autoimmune diseases.
• Promising disease control rates observed for brenetafusp monotherapy in cutaneous melanoma (81-100%) compared to industry benchmarks, supporting its potential in first-line treatment.
• IMC-M113V in HIV Phase 1 trial shows significant reduction in cell-associated HIV Gag RNA and a trend of reduction in intact HIV DNA after completion of multiple dose schedule, along with delayed viral rebound and/or control of viremia at target doses, indicating progress towards a functional cure.

Negatives

• The reported cash position is preliminary and unaudited, subject to material adjustments pending completion of the company's audited financial statements.
• KIMMTRAK revenue growth is expected to be moderating in 2026, suggesting a potential slowdown from previous rapid growth phases.

Risks

• Impact of worsening macroeconomic conditions (e.g., health epidemics, war, geopolitical tension) on business, financial position, strategy, and clinical trials.
• Ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products.
• Ability to obtain and maintain regulatory approval of KIMMTRAK and its other product candidates.
• Ability to establish and expand a commercial infrastructure and successfully launch, market, and sell KIMMTRAK and any future approved products.
• Ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval in additional geographies.
• Delays in current or planned clinical trials due to patient enrollment or other factors.
• Ability to successfully demonstrate the safety and efficacy of product candidates and gain approval on a timely basis, if at all.
• Competition with respect to market opportunities.
• Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
• Actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials or future regulatory approval.
• Need for and ability to obtain additional funding, on favorable terms or at all, especially given macroeconomic conditions.
• Ability to obtain, maintain, and enforce intellectual property protection for KIMMTRAK or any product candidates.
• Success of current and future collaborations, partnerships, or licensing arrangements.
• The preliminary unaudited cash position is subject to change, and adjustments could be material.

Future Outlook

Immunocore anticipates continued commercial excellence for KIMMTRAK, with moderating revenue growth in 2026 driven by increased US community and global market penetration. The company expects significant clinical milestones in 2026, including completion of enrollment for the TEBE-AM Phase 3 trial with potential for topline data, multiple data readouts for PRAME programs in various cancers, and the initiation of clinical trials for autoimmune candidates. Further data from the HIV program and initial data from the PIWIL1 program are also expected in 2026 and 2027, respectively, indicating a broad and active pipeline development strategy.

Management Comments

• "2026 will be an important year for Immunocore. We are building a leading melanoma franchise first with KIMMTRAK, the standard of care for HLA-A*02:01-positive patients with metastatic uveal melanoma, and next in cutaneous melanoma through the TEBE-AM Phase 3 trial, which is our top priority for 2026." Bahija Jallal, CEO of Immunocore.
• "We expect to complete enrollment in the first half, positioning us for data readout as early as the second half of the year. We also continue to advance our broad pipeline, with pivotal readouts in oncology and infectious diseases, and dosing of the first patient in our first autoimmune trial this year." Bahija Jallal, CEO of Immunocore.
• "We have a significant amount of data for our PRAME bispecific candidates, as monotherapy and combinations, and are enrolling patients in our first-line cutaneous melanoma Phase 3 trial." David Berman, Head of Research & Development.
• "In the second half of 2026, we plan to share clinical data from both brenetafusp in ovarian and lung cancer and IMC-P115C, our PRAME half-life extended candidate, which will inform next development steps." David Berman, Head of Research & Development.

Industry Context

Immunocore is positioned as a pioneer in TCR bispecific immunotherapies (ImmTAX platform), targeting a broad range of diseases including cancer, autoimmune, and infectious diseases. This strategy aligns with the industry trend towards precision medicine and leveraging the immune system for therapeutic benefit. Their focus on melanoma, HIV, and autoimmune conditions addresses areas with high unmet medical needs. The company's off-the-shelf approach for ImmTAC molecules offers a potential advantage over personalized cell therapies, which are often complex and costly. The expansion into autoimmune diseases with tissue-specific immune downmodulation represents an innovative approach to a challenging therapeutic area.

Comparison to Industry Standards

• KIMMTRAK is highlighted as the global standard of care in first-line metastatic uveal melanoma, indicating a leading position in this specific indication.
• KIMMTRAK demonstrated a median Overall Survival (OS) of 28 months in metastatic uveal melanoma, with 27% of patients alive at 3 years, compared to 18% for investigator's choice (IC), showcasing superior efficacy.
• In previously treated cutaneous melanoma, KIMMTRAK (tebentafusp) + durvalumab showed 1-year OS of 75% and 2-year OS of 22-23% for patients who progressed on prior anti-PD1, compared to a benchmark of 55% 1-year OS for similar patient populations.
• Brenetafusp monotherapy in cutaneous melanoma demonstrated a Disease Control Rate (DCR) of 81-100% (PRAME positive group), which is promising when compared to nivolumab (DCR 40%) and relatlimab + nivolumab (DCR 49% in 1L, 56% in 2L+).
• In platinum-resistant ovarian cancer, brenetafusp monotherapy achieved a DCR of 58% and an ORR of 6% with a median PFS of 3.3 months, which compares favorably to typical non-platinum chemotherapy (ORR ~<10%, DCR ~40-50%) and provides an alternative to ADCs like mirvetuximab (ORR 42%, DCR 80% for FRa positive patients).

Stakeholder Impact

• **Shareholders/Investors**: Positive impact due to strong cash position, active and progressing clinical pipeline, and multiple upcoming data catalysts that could drive future value. Moderating revenue growth for KIMMTRAK might temper expectations slightly but is offset by pipeline expansion.
• **Patients**: Highly positive impact, as the company is advancing transformative immunomodulating medicines for cancer, infectious diseases (HIV), and autoimmune diseases (type 1 diabetes, atopic dermatitis), addressing significant unmet medical needs.
• **Employees**: Positive impact from a stable financial position and a robust pipeline, suggesting continued growth and development opportunities within the company.
• **Healthcare Providers**: Potential for new and improved treatment options for patients with challenging diseases, particularly in melanoma where KIMMTRAK is already a standard of care and new indications are being pursued.
• **Regulatory Authorities**: Ongoing engagement through clinical trial applications, data submissions, and potential future marketing approvals for new indications and candidates.

Next Steps

• Continue to grow KIMMTRAK's commercial reach in metastatic uveal melanoma through US community and global market penetration.
• Complete enrollment of the Phase 3 TEBE-AM trial in previously treated cutaneous melanoma in 1H 2026.
• Present long-term 5-year Overall Survival (OS) data from the Phase 3 tebentafusp trial in metastatic uveal melanoma in 1H 2026.
• Dose the first patient in the Phase 1 trial for type 1 diabetes (IMC-S118AI) in 1H 2026.
• Present topline data from the Phase 3 TEBE-AM trial as early as 2H 2026.
• Present data from Phase 1/2 brenetafusp combinations in ovarian and non-small cell lung cancer in 2H 2026.
• Present initial data from the Phase 1 trial with IMC-P115C (PRAME-A02-HLE) in multiple solid tumors in 2H 2026.
• Present additional data from the Phase 1 HIV trial (IMC-M113V) in 2H 2026.
• File a clinical trial application/Investigational New Drug application for a Phase 1 trial in atopic dermatitis (IMC-U120AI) in 2H 2026.
• Continue enrollment in Phase 3 registrational adjuvant uveal melanoma trial (ATOM) and Phase 3 brenetafusp combination trial in 1L cutaneous melanoma (PRISM-MEL-301).
• Report final and complete fourth-quarter and full-year 2025 financial results in late February 2026.
• Present initial data from Phase 1 dose escalation in colorectal cancer (PIWIL1 program) in 2027.

Key Dates

Recommendation

Immunocore presents a compelling investment case with a robust preliminary cash position of $864 million, providing substantial financial flexibility. The company is executing on a broad and deep clinical pipeline across oncology, infectious diseases, and autoimmune disorders, with multiple significant data readouts and trial initiations expected in 2026. KIMMTRAK, an already approved and standard-of-care product, continues to expand its market reach, while promising early-stage data for new candidates like brenetafusp and IMC-M113V suggest strong future growth potential. The strategic focus on high-unmet-need areas and the innovative ImmTAX platform position Immunocore for long-term success. The upcoming J.P. Morgan Healthcare Conference presentation and numerous catalysts throughout the year are likely to generate significant investor interest and potential share price appreciation.

Keywords

Immunocore, IMCR, Biotechnology, Oncology, Metastatic Uveal Melanoma, Cutaneous Melanoma, KIMMTRAK, Tebentafusp, PRAME, Brenetafusp, HIV, Type 1 Diabetes, Atopic Dermatitis, Autoimmune Diseases, Infectious Diseases, Clinical Trials, Phase 3, ImmTAC, ImmTAV, ImmTAAI, Biologics, TCR Therapeutics, Pipeline, Cash Position